LINK . SPRINGER . COM {}

Detected CMS Systems:

Serendipity (4 occurrences)

Analyzed Page
Matching Content Categories
CMS
Monthly Traffic Estimate
How Does Link.springer.com Make Money
Keywords
Topics
Questions
Schema
External Links
Analytics And Tracking
Libraries
CDN Services

We are analyzing https://link.springer.com/article/10.1186/s40364-024-00638-1.

Title:
Targeted protein degradation in hematologic malignancies: clinical progression towards novel therapeutics | Biomarker Research
Description:
Targeted therapies, such as small molecule kinase inhibitors, have made significant progress in the treatment of hematologic malignancies by directly modulating protein activity. However, issues such as drug toxicity, drug resistance due to target mutations, and the absence of key active sites limit the therapeutic efficacy of these drugs. Targeted protein degradation (TPD) presents an emergent and rapidly evolving therapeutic approach that selectively targets proteins of interest (POI) based on endogenous degradation processes. With an event-driven pharmacology of action, TPD achieves efficacy with catalytic amounts, avoiding drug-related toxicity. Furthermore, TPD has the unique mode of degrading the entire POI, such that resistance derived from mutations in the targeted protein has less impact on its degradation function. Proteolysis-targeting chimeras (PROTACs) and molecular glue degraders (MGDs) are the most maturely developed TPD techniques. In this review, we focus on both preclinical experiments and clinical trials to provide a comprehensive summary of the safety and clinical effectiveness of PROTACs and MGDs in hematologic malignancies over the past two decades. In addition, we also delineate the challenges and opportunities associated with these burgeoning degradation techniques. TPD, as an approach to the precise degradation of specific proteins, provides an important impetus for its future application in the treatment of patients with hematologic malignancies.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Education
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Link.springer.com is powered by SERENDIPITY.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don't see any clear sign of profit-making.

While profit motivates many websites, others exist to inspire, entertain, or provide valuable resources. Websites have a variety of goals. And this might be one of them. Link.springer.com could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {🔍}

pubmed, article, google, scholar, degradation, cas, patients, protacs, protein, central, tpd, cell, targeted, blood, cells, malignancies, poi, leukemia, proteins, ligase, treatment, clinical, ikzf, wang, btk, chem, lymphoma, degrader, hematologic, cancer, target, tumor, ubiquitin, molecular, supplement, aml, refractory, degraders, relapsed, techniques, activity, crbn, gspt, zhang, multiple, drug, efficacy, phase, med, therapeutic,

Topics {✒️}

anti-b-cell maturation antigen receptor-mediated internalization pro-protacs b-cell lymphoma-extra-large il-6/jak/stat3 signalling axis article google scholar von hippel-lindau protein cul2-rbx1-elobc-vhl b-cell receptor signaling numerous bcl-xl-dependent cancer proteolysis-targeting chimera technology recruiting von hippel-lindau article download pdf b-cell receptor inhibitors stat3-dependent t-cell lymphomas chaperone-mediated protein degrader heterobifunctional small-molecule degraders anti-cd20 monoclonal antibody e1 ubiquitin-activating enzymes germinal center b-cells chaperone-mediated protein degraders single-stranded oligonucleotide sequence e2 ubiquitin-coupling enzymes full-length crbn protein chaperone-mediated protein degradation philadelphia chromosome-positive leukemia g-rich oligonucleotide as1411 selective small-molecule degrader taishan scholars program acute lymphoblastic leukemia myc-dependent cell lines refractory b-cell malignancies selective bcl-xl degrader small molecule-based protac molecularly targeted therapeutics genome-wide crispr screen myd88-mutant preclinical model cgmp-based degradation tag peripheral t-cell lymphoma tumor-targeted protein degradation refractory b-cell nhl showing enhanced anti-proliferative malignant b-cell malignancies proteasomal degradation pathway central nervous system acute myeloid leukemia human x-linked agammaglobulinemia nf-κb pathway hypoxia-inducible transcription factor indisulam-mediated rbm39 recruitment nf-kb pathway activation

Questions {❓}

How Big Is Too Big for Cell Permeability?
Pharmacokinetics/Pharmacodynamic (PK/PD) relationship of therapeutic monoclonal antibodies used in oncology: what’s new?
Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones?
What is the functional role of the thalidomide binding protein cereblon?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Targeted protein degradation in hematologic malignancies: clinical progression towards novel therapeutics
         description:Targeted therapies, such as small molecule kinase inhibitors, have made significant progress in the treatment of hematologic malignancies by directly modulating protein activity. However, issues such as drug toxicity, drug resistance due to target mutations, and the absence of key active sites limit the therapeutic efficacy of these drugs. Targeted protein degradation (TPD) presents an emergent and rapidly evolving therapeutic approach that selectively targets proteins of interest (POI) based on endogenous degradation processes. With an event-driven pharmacology of action, TPD achieves efficacy with catalytic amounts, avoiding drug-related toxicity. Furthermore, TPD has the unique mode of degrading the entire POI, such that resistance derived from mutations in the targeted protein has less impact on its degradation function. Proteolysis-targeting chimeras (PROTACs) and molecular glue degraders (MGDs) are the most maturely developed TPD techniques. In this review, we focus on both preclinical experiments and clinical trials to provide a comprehensive summary of the safety and clinical effectiveness of PROTACs and MGDs in hematologic malignancies over the past two decades. In addition, we also delineate the challenges and opportunities associated with these burgeoning degradation techniques. TPD, as an approach to the precise degradation of specific proteins, provides an important impetus for its future application in the treatment of patients with hematologic malignancies.
         datePublished:2024-08-21T00:00:00Z
         dateModified:2024-08-21T00:00:00Z
         pageStart:1
         pageEnd:24
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s40364-024-00638-1
         keywords:
            Targeted protein degradation
            Hematologic malignancies
            Clinical trials
            Preclinical
            Proteolysis-targeting chimeras
            Molecular glue
            Biomedicine
            general
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40364-024-00638-1/MediaObjects/40364_2024_638_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40364-024-00638-1/MediaObjects/40364_2024_638_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40364-024-00638-1/MediaObjects/40364_2024_638_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40364-024-00638-1/MediaObjects/40364_2024_638_Fig4_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40364-024-00638-1/MediaObjects/40364_2024_638_Fig5_HTML.png
         isPartOf:
            name:Biomarker Research
            issn:
               2050-7771
            volumeNumber:12
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Yupiao Feng
               affiliation:
                     name:Shandong Provincial Hospital, Shandong University
                     address:
                        name:Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Xinting Hu
               affiliation:
                     name:Shandong Provincial Hospital, Shandong University
                     address:
                        name:Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, China
                        type:PostalAddress
                     type:Organization
                     name:Shandong Provincial Hospital Affiliated to Shandong First Medical University
                     address:
                        name:Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Xin Wang
               affiliation:
                     name:Shandong Provincial Hospital, Shandong University
                     address:
                        name:Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, China
                        type:PostalAddress
                     type:Organization
                     name:Shandong Provincial Hospital Affiliated to Shandong First Medical University
                     address:
                        name:Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
                        type:PostalAddress
                     type:Organization
                     name:Taishan Scholars Program of Shandong Province
                     address:
                        name:Taishan Scholars Program of Shandong Province, Jinan, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Targeted protein degradation in hematologic malignancies: clinical progression towards novel therapeutics
      description:Targeted therapies, such as small molecule kinase inhibitors, have made significant progress in the treatment of hematologic malignancies by directly modulating protein activity. However, issues such as drug toxicity, drug resistance due to target mutations, and the absence of key active sites limit the therapeutic efficacy of these drugs. Targeted protein degradation (TPD) presents an emergent and rapidly evolving therapeutic approach that selectively targets proteins of interest (POI) based on endogenous degradation processes. With an event-driven pharmacology of action, TPD achieves efficacy with catalytic amounts, avoiding drug-related toxicity. Furthermore, TPD has the unique mode of degrading the entire POI, such that resistance derived from mutations in the targeted protein has less impact on its degradation function. Proteolysis-targeting chimeras (PROTACs) and molecular glue degraders (MGDs) are the most maturely developed TPD techniques. In this review, we focus on both preclinical experiments and clinical trials to provide a comprehensive summary of the safety and clinical effectiveness of PROTACs and MGDs in hematologic malignancies over the past two decades. In addition, we also delineate the challenges and opportunities associated with these burgeoning degradation techniques. TPD, as an approach to the precise degradation of specific proteins, provides an important impetus for its future application in the treatment of patients with hematologic malignancies.
      datePublished:2024-08-21T00:00:00Z
      dateModified:2024-08-21T00:00:00Z
      pageStart:1
      pageEnd:24
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s40364-024-00638-1
      keywords:
         Targeted protein degradation
         Hematologic malignancies
         Clinical trials
         Preclinical
         Proteolysis-targeting chimeras
         Molecular glue
         Biomedicine
         general
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40364-024-00638-1/MediaObjects/40364_2024_638_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40364-024-00638-1/MediaObjects/40364_2024_638_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40364-024-00638-1/MediaObjects/40364_2024_638_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40364-024-00638-1/MediaObjects/40364_2024_638_Fig4_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40364-024-00638-1/MediaObjects/40364_2024_638_Fig5_HTML.png
      isPartOf:
         name:Biomarker Research
         issn:
            2050-7771
         volumeNumber:12
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Yupiao Feng
            affiliation:
                  name:Shandong Provincial Hospital, Shandong University
                  address:
                     name:Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Xinting Hu
            affiliation:
                  name:Shandong Provincial Hospital, Shandong University
                  address:
                     name:Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, China
                     type:PostalAddress
                  type:Organization
                  name:Shandong Provincial Hospital Affiliated to Shandong First Medical University
                  address:
                     name:Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Xin Wang
            affiliation:
                  name:Shandong Provincial Hospital, Shandong University
                  address:
                     name:Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, China
                     type:PostalAddress
                  type:Organization
                  name:Shandong Provincial Hospital Affiliated to Shandong First Medical University
                  address:
                     name:Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
                     type:PostalAddress
                  type:Organization
                  name:Taishan Scholars Program of Shandong Province
                  address:
                     name:Taishan Scholars Program of Shandong Province, Jinan, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Biomarker Research
      issn:
         2050-7771
      volumeNumber:12
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Shandong Provincial Hospital, Shandong University
      address:
         name:Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, China
         type:PostalAddress
      name:Shandong Provincial Hospital, Shandong University
      address:
         name:Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, China
         type:PostalAddress
      name:Shandong Provincial Hospital Affiliated to Shandong First Medical University
      address:
         name:Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
         type:PostalAddress
      name:Shandong Provincial Hospital, Shandong University
      address:
         name:Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, China
         type:PostalAddress
      name:Shandong Provincial Hospital Affiliated to Shandong First Medical University
      address:
         name:Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
         type:PostalAddress
      name:Taishan Scholars Program of Shandong Province
      address:
         name:Taishan Scholars Program of Shandong Province, Jinan, China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Yupiao Feng
      affiliation:
            name:Shandong Provincial Hospital, Shandong University
            address:
               name:Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, China
               type:PostalAddress
            type:Organization
      name:Xinting Hu
      affiliation:
            name:Shandong Provincial Hospital, Shandong University
            address:
               name:Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, China
               type:PostalAddress
            type:Organization
            name:Shandong Provincial Hospital Affiliated to Shandong First Medical University
            address:
               name:Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Xin Wang
      affiliation:
            name:Shandong Provincial Hospital, Shandong University
            address:
               name:Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, China
               type:PostalAddress
            type:Organization
            name:Shandong Provincial Hospital Affiliated to Shandong First Medical University
            address:
               name:Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
               type:PostalAddress
            type:Organization
            name:Taishan Scholars Program of Shandong Province
            address:
               name:Taishan Scholars Program of Shandong Province, Jinan, China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, China
      name:Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, China
      name:Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
      name:Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, China
      name:Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
      name:Taishan Scholars Program of Shandong Province, Jinan, China

External Links {🔗}(596)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.91s.